2012
DOI: 10.1002/cbic.201200007
|View full text |Cite
|
Sign up to set email alerts
|

The Carmaphycins: New Proteasome Inhibitors Exhibiting an α,β‐Epoxyketone Warhead from a Marine Cyanobacterium

Abstract: Two new peptidic proteasome inhibitors were isolated as trace components from a Curaçao collection of Symploca sp. marine cyanobacteria. Carmaphycin A (1) and carmaphycin B (2) feature a leucine-derived α, β -epoxyketone warhead directly connected to either methionine sulfoxide or methionine sulfone. Their structures were elucidated on the basis of extensive NMR/MS analyses and confirmed by total synthesis, which in turn provided more material for further biological evaluations. Pure carmaphycins A and B were … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

2
112
0
1

Year Published

2013
2013
2017
2017

Publication Types

Select...
4
2
1

Relationship

0
7

Authors

Journals

citations
Cited by 116 publications
(115 citation statements)
references
References 44 publications
2
112
0
1
Order By: Relevance
“…27.7) having potent anti-proteasome properties were isolated in small amounts from Symploca sp. obtained from CARMABI beach, Curacao [88]. These compounds are structurally related to the known proteasome inhibitor, epoxomicin, in having a terminal α,β-epoxyketone moiety and a methionine sulfoxide in 40 or methionine sulfone in 41.…”
Section: Carmaphycinsmentioning
confidence: 99%
See 1 more Smart Citation
“…27.7) having potent anti-proteasome properties were isolated in small amounts from Symploca sp. obtained from CARMABI beach, Curacao [88]. These compounds are structurally related to the known proteasome inhibitor, epoxomicin, in having a terminal α,β-epoxyketone moiety and a methionine sulfoxide in 40 or methionine sulfone in 41.…”
Section: Carmaphycinsmentioning
confidence: 99%
“…These compounds are structurally related to the known proteasome inhibitor, epoxomicin, in having a terminal α,β-epoxyketone moiety and a methionine sulfoxide in 40 or methionine sulfone in 41. As part of the drug development process, their total synthesis was also accomplished using an efficient and scalable convergent method [88]. The inhibitory properties of carmaphycins A and B were evaluated against Saccharomyces cerevisiae 20S proteasome and found to possess comparable IC 50 values of 2.5 nM and 2.6 nM, respectively.…”
Section: Carmaphycinsmentioning
confidence: 99%
“…6). 123 These compounds are characterized by a tripeptide moiety fused to a hexanoic acid and α,β-epoxyketone on the N- and C-terminal ends, respectively. Insights into the MOA of the modified peptides carmaphycins A and B were obtained from the structural similarity of these compounds with the epoxomicin class of compounds.…”
Section: Mechanisms Of Action and Direct Cellular Targets Of Biologmentioning
confidence: 99%
“…Insights into the MOA of the modified peptides carmaphycins A and B were obtained from the structural similarity of these compounds with the epoxomicin class of compounds. 123 Carmaphycins and epoxomicins are characterized by an α,β-epoxyketone that has been demonstrated to be one of the key features in the latter for inhibiting the proteasome, forming a covalent bond with the catalytic Thr residue of the β5 subunit. 121 Carmaphycins inhibited the chymotrypsin-like (β5 subunit) activity of the 20S proteasome, with comparable potency to epoxomicin, culminating in potent inhibition of the growth of cancer cells, particularly those which harbor KRAS/tp53 mutations.…”
Section: Mechanisms Of Action and Direct Cellular Targets Of Biologmentioning
confidence: 99%
See 1 more Smart Citation